Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome - 26/08/11
, Wen-Jone Chen, MD, PhD b, Jong-Wei Lin, BS a, Ming-Fong Chen, MD, PhD a, Yuan-Teh Lee, MD, PhD aAbstract |
Fifty nondiabetic patients who met a modified National Cholesterol Education Program definition for the metabolic syndrome were randomized to receive either rosiglitazone (4 mg/day; n = 25) or placebo (n = 25) for 8 weeks. Compared with those receiving placebo, patients in the rosiglitazone group achieved significant reductions in fasting plasma insulin levels (−40%), homeostasis model assessment indexes (−45%), systolic and diastolic blood pressures, and high-sensitivity C-reactive protein levels (−31%). There were no changes in fasting plasma glucose with either treatment. Although rosiglitazone treatment greatly increased plasma levels of low-density lipoprotein cholesterol (18%) and apolipoprotein B (16%), it significantly improved both endothelium-dependent flow-mediated vasodilation (p <0.001) and endothelium-independent nitroglycerin-induced vasodilation (p = 0.01) of the right brachial artery.
Le texte complet de cet article est disponible en PDF.
Vol 93 - N° 3
P. 362-365 - février 2004 Retour au numéro
Article précédent
- Duration of residence in the United States as a new risk factor for coronary artery disease (The Konkani Heart Study)
- Shanthalaxmi N. Mooteri, Floyd Petersen, Ramesh Dagubati, Ramdas G. Pai
- Effect of direct-current cardioversion on ischemia- modified albumin levels in patients with atrial fibrillation
- Debashis Roy, Juan Quiles, Manas Sinha, Guillermo Aldama, David Gaze, Juan Carlos Kaski
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?